公开(公告)号：US09295667B2

公开(公告)日：2016-03-29

申请号：US14178090

申请日：2014-02-11

Applicant: Korea Basic Science Institute

Inventor： Gun-Hwa Kim ,  Soohyun Kim ,  Jong-Soon Choi ,  Seung Il Kim ,  Edmond Changkyun Park

IPC: A61K31/41 ,  A61K31/415 ,  A61K31/20 ,  A61K31/18 ,  A61K31/15 ,  A61K31/4192 ,  A61K31/155 ,  A61K31/201 ,  A61K31/4174

CPC classification number: A61K31/4192 ,  A61K31/15 ,  A61K31/155 ,  A61K31/18 ,  A61K31/201 ,  A61K31/4174

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver, and more specifically relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A (cytochrome P450A) inhibitor as an active ingredient. According to the present invention, the CYP4A inhibitor suppresses endoplasmic reticulum stress, reduces the blood insulin concentration and suppresses apoptosis of liver cells, and hence exhibits effects in preventing or treating diabetes or fatty liver.

Abstract translation: 本发明涉及用于预防或治疗糖尿病或脂肪肝的药物组合物，更具体地涉及含有CYP4A（细胞色素P450A）抑制剂作为活性成分的糖尿病或脂肪肝的预防或治疗药物组合物。 根据本发明，CYP4A抑制剂抑制内质网应激，降低血胰岛素浓度，抑制肝细胞凋亡，因此具有预防或治疗糖尿病或脂肪肝的作用。